Bexson Biomedical, Inc.

Bexson Biomedical, Inc. is a US-based company focused on advancing drug delivery systems through innovative technology, enhancing the bioavailability of therapeutic agents for improved patient care. Founded in 2017 and headquartered in Santa Barbara, US, Bexson Biomedical specializes in drug delivery solutions. The company has undergone significant advancements in its operational strategy, particularly with its focus on the proprietary 7-valence salt technology.

CEO Gregg Peterson leads the company, which raised USD 4. 8 mn in Series A funding on February 2, 2021, with Noetic Fund as the lead investor. The company has successfully raised a total of USD 4. 8 mn to date through this funding round.

Bexson Biomedical focuses on enhancing drug delivery through its innovative 7-valence salt technology, which significantly improves the subcutaneous delivery of small molecules. This core product aims to potentiate the bioavailability of existing therapeutic agents, thereby unlocking new routes of administration that can solve challenges faced by patients requiring precise dosing. The company's products cater to a wide array of healthcare applications, targeting both chronic and acute health conditions, and serve a diverse client base that includes healthcare providers, pharmaceutical companies, and research institutions, primarily in North America and Europe. Bexson Biomedical's revenue model revolves around strategic partnerships and B2B transactions, leveraging its proprietary technology to offer tailored solutions for pharmaceutical clients.

The company engages in direct sales to healthcare providers and collaborates with industry partners to facilitate the distribution of its advanced drug delivery systems. Revenue is generated through contractual agreements that may involve licensing fees and product sales, with clients benefitting from access to Bexson's flagship 7-valence salt products. Additionally, the company may implement subscription-based models for continuous support and product updates, ensuring clients receive ongoing value from their partnership. In February 2021, Bexson Biomedical raised USD 4.

8 mn in Series A funding, which will support the pre-clinical and GMP manufacturing scale-up for its proprietary ketamine formulation, BB106. The funding will also aid in developing a wearable delivery device in collaboration with the leading medical device manufacturer, Stevanato Group. The company is focused on expanding its market presence, particularly in North America and Europe, by launching new products that cater to the evolving needs of patients requiring innovative drug delivery solutions.